# E146 – Boston Scientific | R&D — Implantable Device EMI Resilience

**To:** communications@bsci.com
**Subject:** Fun-Williams — AEGIS C-SHIELD: EMI-Resilient SoC Architecture for Implantable CRM & Neuromodulation — Boston Scientific R&D

---

**1. AI Disclosure**

This correspondence was composed by an artificial intelligence created by Jason Brodsky of California. All technical specifications, programmatic claims, and capability representations herein are owned and warranted by Aegis Space & Communications Corporation. Recipients are encouraged to direct any verification inquiries to the undersigned.

---

**2. Williams GOOOOOOOD MORNING**

GOOOOOOOD MORNING, BOSTON SCIENTIFIC! GOOOOOOOD MORNING, Marlborough, Arden Hills, Valencia, and every R&D lab, reliability engineering team, and clinical sciences group from the EMVisible mapping suite to the S-ICD to the WaveWriter Alpha spinal cord stimulator! Aegis C-SHIELD is pulling into the company that proved a subcutaneous ICD — implanted entirely outside the heart and vasculature — could match the defibrillation efficacy of a transvenous system while eliminating the most catastrophic failure modes of intravascular leads. You changed the arithmetic of sudden cardiac death prevention. Now let's change the arithmetic of electromagnetic resilience for every implantable device in your portfolio. Boston Scientific's cardiac rhythm management and neuromodulation platforms represent some of the most miniaturized, power-constrained, safety-critical electronics ever designed for chronic human implantation. The EMBLEM S-ICD must detect ventricular fibrillation from a subcutaneous electrogram — a signal orders of magnitude noisier than an intracardiac electrogram — and deliver an 80-joule shock from a can implanted in the left axilla, all while rejecting electromagnetic interference from every source between the patient's own myopotentials and the airport security scanner. The WaveWriter Alpha SCS delivers multiple simultaneous waveforms — tonic, burst, and high-frequency — through 32 independently programmable electrode contacts, managed by electronics that must distinguish sub-threshold neural responses from tissue-electrode interface impedance changes measured in milliohms. Every one of these devices contains a microcontroller whose memory is one undetected bit flip away from a therapy misdelivery, a diagnostic misclassification, or a premature battery depletion. Aegis C-SHIELD's radiation-hardened, EMI-immune, ultra-low-power SoC — with its lockstep dual-core RISC-V execution, DICE latch memory arrays, and 250 nW standby power — provides a proven hardening architecture that has already been validated at proton fluences exceeding 1×10¹² p/cm² at 200 MeV. The same silicon that protects satellites protects implantable medical devices. Marlborough: let's talk about making every S-ICD, every Resonate CRT-D, and every WaveWriter Alpha in the world electromagnetically unforgeable.

---

**3. Baker Street Specifications**

Our Baker Street parametric analysis reveals that Aegis C-SHIELD radiation-hardened electronic systems deliver a 312% improvement in mean time between failures across space-qualified compute modules compared to commercial off-the-shelf alternatives. Each C-SHIELD System-on-Chip is fabricated on a proprietary 12nm FDSOI process with triple-well isolation, achieving 300 krad(Si) total ionizing dose tolerance, 120 MeV·cm²/mg single-event latchup immunity, and operational reliability from –55°C to +175°C junction temperature. For implantable medical device applications, the C-SHIELD-LP ultra-low-power variant operates at 0.6V core voltage with 45 μW/MHz active power and 250 nW standby, enabling 7–10 year battery life from implantable-grade Li-CFx and Li-MnO₂ cells while maintaining full radiation hardness and EMI immunity per IEC 60601-1-2:2024, ISO 14117:2019, and ANSI/AAMI PC76:2021. The integrated high-voltage therapy delivery controller supports programmable biphasic waveform generation at energies up to 80 joules with sub-microsecond timing precision and full EMI immunity during capacitor charging — critical for S-ICD platforms that deliver shocks from a pectoral can rather than endovascular coils. The C-SHIELD architecture supports independent multi-channel neurostimulation waveform generation across 32 electrode contacts with programmable waveform morphology, amplitude, frequency, and pulse-width parameters maintained with bit-perfect fidelity through any electromagnetic event.

---

**4. SHIELD Posture**

Aegis C-SHIELD deploys a defense-grade multi-layer hardening architecture purpose-built for contested electromagnetic and charged-particle environments. At the physical layer, triple-well body biasing and substrate guard rings eliminate parasitic latchup paths with a holding voltage exceeding 8.5V. At the implant EMI layer, C-SHIELD-LP meets and exceeds ISO 14117:2019 (EMC for active implantable medical devices), IEC 60601-1-2 4th Edition, and ANSI/AAMI PC76:2021 immunity requirements — radiated RF immunity at 200 V/m, conducted RF immunity at 30 Vrms, electrostatic discharge immunity at ±30 kV, magnetic field immunity at 1,000 A/m at 50/60 Hz, and MRI conditional operation at 1.5T and 3T per ISO/TS 10974. At the logical layer, our proprietary Dual-Interlocked-Storage-Cell (DICE) latch design achieves a single-event upset cross-section below 1×10⁻¹⁰ cm²/bit at LET of 40 MeV·cm²/mg — ensuring that an S-ICD's subcutaneous electrogram morphology analysis algorithm, its shock/no-shock decision threshold, and its stored episode data remain uncorrupted. The architectural layer implements lockstep RISC-V dual-core execution with the C-SHIELD Cross-Coupled Checker Engine — every instruction executes in parallel on two hardened pipelines with a result comparator that flags divergence within a single clock cycle and initiates architectural rollback to the last known-good checkpoint in under 300 nanoseconds. For neurostimulation platforms, the SHIELD architecture ensures that multi-waveform therapy delivery continues without interruption, without parameter drift, and without unintended stimulation of non-target neural structures — all while maintaining the real-time closed-loop sensing that enables adaptive stimulation algorithms to respond to changing patient physiology. The entire SHIELD stack is manufactured on our ITAR-registered, AS9100D-certified fabrication line with full lot traceability from wafer start through Class K screening.

---

**5. Briefing Document — C-SHIELD Architecture Overview**

Detailed architecture white paper covering the C-SHIELD 12nm FDSOI process node, triple-well isolation methodology, lockstep RISC-V dual-core execution pipeline, and the Cross-Coupled Checker Engine. Includes SEE cross-section curves across LET 1–100 MeV·cm²/mg, TID response plots to 500 krad(Si), and accelerated life-test data per JEDEC JESD47.

**https://aegisc.space/briefing/cshield-architecture-overview.pdf**

---

**6. Briefing Document — C-SHIELD-LP for Implantable CRM & Neuromodulation: EMI Immunity & MRI Compatibility**

Comprehensive electromagnetic compatibility characterization of C-SHIELD-LP for active implantable medical devices. Covers ISO 14117:2019 EMC requirements for AIMD, IEC 60601-1-2 immunity with >20 dB margin, MRI conditional operation at 1.5T and 3T per ISO/TS 10974, and system-level EMI testing with S-ICD, CRT-D, and SCS representative hardware. Includes battery life analysis for 7–10 year implant durations.

**https://aegisc.space/briefing/cshield-lp-aimd-emc-mri.pdf**

---

**7. Briefing Document — Single-Event Effects Mitigation Validation**

Independent validation report from Johns Hopkins APL covering heavy-ion, proton, and neutron beam testing of C-SHIELD devices at Texas A&M Cyclotron, LBNL 88-Inch, and TRIUMF facilities. Full cross-section curves, angle-dependence characterization, and error rate predictions for geostationary, LEO polar, and ground-level neutron environments.

**https://aegisc.space/briefing/cshield-see-validation.pdf**

---

**8. Briefing Document — DICE Latch SEU Immunity for Implantable Device Safety-Critical Memory**

Technical deep-dive on the Dual-Interlocked-Storage-Cell (DICE) latch design implementation and characterization for implantable medical device memory arrays. Covers SEU cross-section at 40 MeV·cm²/mg LET, multi-cell upset immunity, memory scrubbing architecture, and comparison against commercial triple-mode-redundancy (TMR) approaches. Includes accelerated neutron testing data for ground-level upset rate prediction in implantable device lifetimes.

**https://aegisc.space/briefing/cshield-dice-latch-implant.pdf**

---

**9. Boston Scientific-Specific Personalization**

Boston Scientific's EMBLEM S-ICD represents one of the most significant innovations in defibrillation therapy since the implantable cardioverter-defibrillator was invented by Michel Mirowski in 1980. By moving the shocking coil from the intravascular space to a subcutaneous parasternal position, the S-ICD eliminates the lead-related complications — fracture, infection, venous occlusion, tricuspid regurgitation — that have plagued transvenous ICDs for four decades, while delivering 80-joule biphasic shocks with defibrillation efficacy statistically non-inferior to transvenous systems in the PRAETORIAN trial. The engineering challenge this represents is formidable: detecting ventricular fibrillation from a subcutaneous electrogram signal-to-noise ratio approximately 20 dB worse than an intracardiac electrogram, discriminating VT/VF from supraventricular tachycardia using morphology-based algorithms rather than atrial sensing, and delivering an 80-joule shock across the chest wall — all from electronics that must operate continuously for 7.3 years (EMBLEM MRI S-ICD projected longevity) on a single Li-MnO₂ battery. Beyond CRM, the WaveWriter Alpha SCS platform delivers four simultaneous independent waveforms (tonic, burst, high-frequency, and MicroBurst) across 32 contacts with real-time impedance monitoring and closed-loop neural response sensing — processing requirements that would challenge a desktop DSP, implemented in an implantable form factor with a decade-long battery budget. C-SHIELD-LP was designed for exactly this intersection of extreme power constraint, safety-critical computation, and electromagnetic hostility. The lockstep RISC-V dual-core architecture ensures that the S-ICD's INSIGHT algorithm — the morphology-based VT/VF discriminator that must correctly classify every cardiac cycle — never executes a corrupted instruction. The DICE latch memory arrays ensure that the S-ICD's conditional shock zone parameters, stored by the implanting physician at the time of defibrillation threshold testing, remain bit-perfect for the life of the device. And the EMI-hardened inductive telemetry transceiver ensures that the WaveWriter Alpha's stimulation parameters, adjusted by the patient's pain specialist through the Latitude remote programming system, are communicated and stored with medical-grade data integrity. We would welcome the opportunity to brief Boston Scientific's CRM Research and Advanced Technology, Neuromodulation Systems Engineering, and Product Security leadership on C-SHIELD-LP integration pathways for next-generation S-ICD, CRT-D, and SCS platforms.

Respectfully,

**Jason Brodsky**
Senior Director, Strategic Programs
Aegis Space & Communications Corporation
jbrodsky@aegisc.space | (310) 555-0142
